|
1.Bray F, Ferlay J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2.International Agency for Research on Cancer. Globocan 2018: Cancer Fact Sheets — Colorectal Cancer. IARC. Available online: http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum- fact-sheet.pdf (2018) (accessed on 17 Oct 2018)
3.Yue Xi , Pengfei Xu. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021, 14(10):101174
4.Huang YC, Chen YH. Cancer incidence characteristic evolution based on the National Cancer Registry in Taiwan. J Oncol 2020; 2020: 1408793.
5.Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713-732.
6.Campos FG. Colorectal cancer in young adults: A difficult challenge. World J Gastroenterol. 2017;23(28):5041-5044.
7.Guren MG. The global challenge of colorectal cancer. Lancet Gastroenterol Hepatol. 2019;4(12):894-895
8.Peterse EFP, Meester RGS. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. J Natl Cancer Inst. 2021 Feb 1;113(2):154-161.
9.Chen CJ, You SL. Cancer epidemiology and control in Taiwan: A brief review. Jpn J Clin Oncol 2002; 32: S66-S81.
10.Lee CH, Cheng SC. The risk factors affecting survival in colorectal cancer in Taiwan. Iran J Public Health 2018; 47: 519-530.
11.International Agency for Research on Cancer. Globocan 2018: Cancer FactSheets—ColorectalCancer.IARC.http://gco.iarc.fr/today/data/factsheets/ cancers/10_8_9-Colorectum- fact-sheet.pdf (2018).
12.Karastergiou, K., Smith, S. R., Greenberg, A. S. & Fried, S. K. Sex differences in human adipose tissues– the biology of pear shape. Biol. Sex Differ. 3, 13(2012).
13.Wilsnack, R. W., Wilsnack, S. C., Kristjanson, A. F., Vogeltanz- Holm, N. D. & Gmel, G. Gender and alcohol consumption: patterns from the multinational GENACIS project. Addiction 104, 1487–1500 (2009).）
14.World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Smoking. 2015. World Health Organization http://apps.who.int/iris/bitstream/handle/10665/156262/9789241564922_eng.pdf;jsessionid=3E603A72D553D128773D0836AECE325E?sequence=1 (2015).
15.Imamura, F. et al. Dietary quality among men and women in 187 countries in 1990 and 2010:a systematic assessment. Lancet Glob. Health 3, e132–e142 (2015).
16.Huang YC, Chen YH. Cancer incidence characteristic evolution based on the National Cancer Registry in Taiwan. J Oncol 2020; 2020: 1408793. [PMID:32774368 DOI: 10.1155/2020/1408793]
17.Park HC, Shin A, Kim BW, Jung KW, Won YJ, Oh JH, Jeong SY, Yu CS, Lee BH. Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctol. 2013;29:144–149
18.Dow, L. E. et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539–1552 (2015).
19.Leggett, B. & Whitehall, V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138, 2088–2100 (2010).
20.Kedrin, D. & Gala, M. K. Genetics of the serrated pathway to colorectal cancer. Cl
21.Song, M. et al. Long- term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study. Int. J. Epidemiol. 45, 871–883 (2016).
22.Moore, L. L. et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int. J. Obes. Relat. Metab. Disord. 28,559–567 (2004).
23.Bruun, J. M., Lihn, A. S., Pedersen, S. B. & Richelsen, B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90, 2282–2289 (2005).
24.Park, J., Morley, T. S., Kim, M., Clegg, D. J. & Scherer, P. E. Obesity and cancer–mechanisms underlying tumour progression and recurrence. Nat. Rev. Endocrinol. 10, 455–465 (2014).
25.Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591 (2004).
26.Rezende, L. F. M. et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br. J. Sports Med. 52, 826–833 (2018).）
27.World Cancer Research Fund/American Institute for Cancer Research. World Cancer Research Fund Internationl Systematic Literature Review: The Associations between Food, Nutrition and Physical Activity and the Risk of Colorectal Cancer, 2017. World Cancer Research Fund https://www.wcrf.org/sites/default/files/colorectal- cancer-slr.pdf (2017).
28.Schmid, D. & Leitzmann, M. F. Television viewing and time spent sedentary in relation to cancer risk: a metaanalysis. J. Natl Cancer Inst. 106, dju098 (2014).
29.Lynch, B. M. Sedentary behavior and cancer: a systematic review of the literature and proposed biological mechanisms. Cancer Epidemiol. Biomarkers Prev. 19, 2691–2709 (2010).
30.Tabung, F. K., Brown, L. S. & Fung, T. T. Dietary patterns and colorectal cancer risk: a review of 17 years of evidence (2000-2016). Curr. Colorectal Cancer Rep. 13, 440–454 (2017).
31.Holscher, H. D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 8, 172–184 (2017).）
32.Zeng, H., Lazarova, D. L. & Bordonaro, M. Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J. Gastrointest. Oncol. 6, 41–51 (2014).
33.Elce, A. et al. Butyrate modulating effects on proinflammatory pathways in human intestinal epithelial cells. Benef. Microbes 8, 841–847 (2017)）
34.Kunzmann, A. T. et al. Dietary fiber intake and risk of colorectal cancer and incident and recurrent adenoma in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Clin. Nutr. 102, 881–890 (2015).
35.Choi, Y. J., Myung, S. K. & Lee, J. H. Light alcohol drinking and risk of cancer: a meta- analysis of cohort studies. Cancer Res. Treat. 50, 474–487 (2018).
36.Seitz, H. K. & Stickel, F. Molecular mechanisms of alcohol- mediated carcinogenesis. Nat. Rev. Cancer 7, 599–612 (2007).
37.Giovannucci, E. Alcohol, one- carbon metabolism, and colorectal cancer: recent insights from molecular studies. J. Nutr. 134, 2475S–2481S (2004).
38.Giovannucci, E. & Martinez, M. E. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J. Natl Cancer Inst. 88, 1717–1730 (1996).）
39.Johnson, C. M. et al. Meta- analyses of colorectal cancer risk factors. Cancer Causes Control 24, 1207–1222 (2013).
40.Liang, P. S., Chen, T. Y. & Giovannucci, E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta- analysis. Int. J. Cancer 124, 2406–2415 (2009).
41.Shi, Y.; Hu, F.B. The global implications of diabetes and cancer. Lancet 2014, 383, 1947–1948
42.Kirkman, M.S.; Briscoe, V.J.; Clark, N.; Florez, H.; Haas, L.B.; Halter, J.B.; Huang, E.S.; Korytkowski, M.T.; Munshi, M.N.; Odegard, P.S.; et al. Diabetes in Older Adults. Diabetes Care 2012, 35, 2650–2664
43.Suh, S.; Kim, K.-W. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes Metab. J. 2019, 43, 733.
44.Sciacca, L.; Vigneri, R.; Tumminia, A.; Frasca, F.; Squatrito, S.; Frittitta, L. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 808–815.
45.Hirsch, I.B.; Juneja, R.; Beals, J.M.; Antalis, C.J.; E Wright, E. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr. Rev. 2020, 41, 733–755.
46.Giovannucci, E.L.; Harlan, D.M.; Archer, M.C.; Bergenstal, R.M.; Gapstur, S.M.; Habel, L.A.; Pollak, M.; Regensteiner, J.G.; Yee, D. Diabetes and Cancer: A consensus report. Diabetes Care 2010, 33, 1674–1685.
47.Masur, K.; Vetter, C.; Hinz, A.; Tomas, N.; Henrich, H.; Niggemann, B.; Zänker, K.S. Diabetogenic glucose and insulin concentrations modulate transcriptom and protein levels involved in tumour cell migration, adhesion and proliferation. Br. J. Cancer 2010, 104, 345–352.
48.Mendonça, F.M.; de Sousa, F.R.; Barbosa, A.L.; Martins, S.C.; Araújo, R.L.; Soares, R.; Abreu, C. Metabolic syndrome and risk of cancer: Which link? Metabolism 2015, 64, 182–189.
49.Ling, S.; Brown, K.; Miksza, J.K.; Howells, L.; Morrison, A.; Issa, E.; Yates, T.; Khunti, K.; Davies, M.J.; Zaccardi, F. Association of Type 2 Diabetes with Cancer: A Meta-analysis with Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care 2020, 43, 2313–2322.
50.Bjornsdottir, H.H.; Rawshani, A.; Rawshani, A.; Franzén, S.; Svensson, A.-M.; Sattar, N.; Gudbjörnsdottir, S. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci. Rep. 2020, 10, 1–12.
51.Lu,Y.; Tao, J. Diabetes Mellitus and Obesity as Risk Factors for Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12: 699732.
52.Srivastava, S.P.; Goodwin, J.E. Cancer Biology and Prevention in Diabetes. Cells. 2020 Jun 2;9(6):1380.
53.O'Mara B.A., Byers T., Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J. Chron. Dis. 1985;38(5):435–441.
54.Will J.C. Colorectal cancer: another complication of diabetes mellitus? Am. J. Epidemiol. 1998;147(9):816–825
55.Wu L. Diabetes mellitus and the occurrence of colorectal cancer: an updated meta-analysis of cohort studies. Diabetes Technol. Ther. 2013;15(5):419–427.
56.Y.X. Yang , S. Hennessy , J.D. Lewis , Type 2 diabetes mellitus and the risk of colorectal cancer, Clin. Gastroenterol. Hepatol. 3 (6) (2005) 587–594 . 9
57.L. Deng , et al. , Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis, Dig. Dis. Sci. 57 (6) (2012) 1576–1585
58.K.K. Tsilidis , et al. , Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ 350 (2015) g7607 .
59.C.M. Shin , et al. , Association among obesity, metabolic health, and the risk for col- orectal cancer in the general population in Korea using the national health insurance service-national sample cohort, Dis. Colon Rectum. 60 (11) (2017) 1192–1200 .
60.S. de Kort , et al. , Diabetes mellitus type 2 and subsite-specific colorectal cancer risk in men and women: results from the Netherlands cohort study on diet and cancer, Eur. J. Gastroenterol. Hepatol. 28 (8) (2016) 896–903 .
61.Y. Ma , et al. , Type 2 diabetes and risk of colorectal cancer in two large U.S. prospec- tive cohorts, Br. J. Cancer 119 (11) (2018) 1436–1442 .
62.Jeon J.Y. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PLoS One. 2013;8(2):e55196.
63.Brown J.C. Diabetes and clinical outcome in patients with metastatic colorectal cancer: CALGB 80405 (Alliance) JNCI Cancer Spectr. 2020;4(1):pkz078.
64.Rapp K. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49(5):945–952.
65.Shi J. A linear dose-response relationship between fasting plasma glucose and colorectal cancer risk: systematic review and meta-analysis. Sci. Rep. 2015;5:17591.
66.Pang Y. Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: a prospective study of 0.5 million people. J. Epidemiol. Commun. Health. 2018;72(10):919–925.
67.de Haas E, Oosting S, Lefrandt J et al (2010) The metabolic syndrome in cancer survivors. Lancet Oncol 11:193–203.
68.Cornier M, Dabelea D, Hernandez T et al (2008) The metabolic syndrome. Endocr Rev 29:777–822.
69.Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) .The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295–300
70.Li L, Huang HL, Zhang XY, Zhang XY, Lv ZH. Association of metabolic syndrome and colorectal cancer .Chinese journal of gastrointestinal surgery. 2011;14:948–51.
71.Stocks T, Lukanova A, Bjorge T, Ulmer H, Manjer J, Almquist M. et al. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can) Cancer. 2011;117:2398–407.
72.Kabat GC, Kim MY, Peters U, Stefanick M, Hou LF, Wactawski-Wende J. et al. A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. European Journal Of Cancer Prevention. 2012;21:326–32.
73.Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H. et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18:240–7.
74.Liang X, Margolis KL, Hendryx M, Rohan TE, Groessl EJ, Thomson CA. et al. Metabolic phenotype and risk of colorectal cancer in normal-weight postmenopausal women. Cancer Epidemiology Biomarkers and Prevention. 2017;26:155–61.
75.Choi YJ, Lee DH, Han KD, Shin CM, Kim N. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. European journal of epidemiology. 2018;33:1077–85.
76.Milano A, Bianco MA, Buri L, Cipolletta L, Grossi E, Rotondano G, Metabolic syndrome is a risk factor for colorectal adenoma and cancer: a study in a White population using the harmonized criteria. Therapeutic Advances in Gastroenterology. 2019. 12
77.Li X, Chen H, Wang G, Feng X, Lyu Z, Wei L. et al. Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Frontiers in oncology. 2019;9:1047.
78.Esposito K, Chiodini P, Capuano A et al (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44:634–647.
79.Chen H, Zheng X, Zong X et al (2020) Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut
80.Pelucchi C, Negri E, Talamini R et al (2010) Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 46:1866–1872.
81.Xiaoding Shen, Yong Wang, Rui Zhao et al. Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta‑analysis. Int J Colorectal Dis. 2021 Oct;36(10):2215-2225.
82.Komninou D, Ayonote A, Richie J, Rigas B (2003) Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 228:396–405.
83.Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915–928
84.Quail D, Dannenberg A (2019) The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol 15:139–154.
85.Ng C, Jiang A, Toh E et al (2020) Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. Int J Colorectal Dis 35:1501–1512
86.Liu Y, Tang W, Wang J et al (2014) Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer causes & control : CCC 25:237–249.
87.Almazeedi S, El-Abd R, Al-Khamis A, Albatineh A, Al-Sabah S (2020) Role of bariatric surgery in reducing the risk of colorectal cancer: a meta-analysis. Br J Surg 107:348–354.
88.Tornberg SA, Holm LE. Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 1986; 315: 1629-1633.
89.Mamtani R, Lewis JD. Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study. PLoS Med 2016; 13: e1002007.
90.Park SK, Joo JS. Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: A case-control study in Korea. J Korean Med Sci 2000; 15: 690-695.
91.Rodriguez-Broadbent H, Law PJ. Mendelian randomisation implicates hyperlipidaemia as risk factor for colorectal cancer. Int J Cancer 2017; 140: 2701-2708.
92.Sorlie PD, Fienleib M. The serum cholesterol-cancer relationship: An analysis of time trends in the Framingham study. J Natl Cancer Inst 1982; 69: 989-996.
93.Yaari S, Goldbourt E-Z. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men. Lancet 1981; 1: 1011-1015.
94.Agnoli C, Grioni S. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol. 2014;38(2):144-51.
95.Inoue M, Noda M. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240-7.
96.Strohmaier S, Edlinger M. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One. 2013;8(1):e54242.
97.van Duijnhoven FJ, Bueno-De-Mesquita HB. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011;60(8):1094-102.
98.Ahmed RL, Schmitz KH. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28-36.
99.Bowers K, Albanes D. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164(7):652-64.
100.Iso, H, Ikeda, A, Inoue, M et al. (2009) Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 125, 2679–2686
101.Wulaningsih, W, Garmo, H, Holmberg, L et al. (2012) Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS study. J Cancer Epidemiol 2012, 792034.
102.Ulmer, H, Borena, W, Rapp, K et al. (2009) Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 101, 1202–1206.
103.Schoen, RE, Tangen, CM, Kuller, LH et al. (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91, 1147–1154
104.Aleksandrova, K, Boeing, H, Jenab, M et al. (2011) Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 4, 1873–1883.
105.American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-S123.
106.Long J, Zhang C-J. Lipid metabolism and carcinogenesis, cancer development. Am. J. Cancer Res. 2018;8:778–791.
107.Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 2014;24:472–478.
108.Laslett LJ, Alagona P Jr. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S1–49.
109.Xinghua Yang , Chaonan Xu. Risk prediction model of dyslipidaemia over a 5-year period based on the Taiwan MJ health check-up longitudinal database. Lipids Health Dis. 2018;17(1):259.
110.Kuo P, Syu JT. Prevalence and trend of dyslipidaemia from 1996 to 2006 among normal and overweight adolescents in Taiwan. BMJ Open. 2014;4(2):e003800.
111.Cheng KC, Chen YL. Prevalence of dyslipidaemia in patients receiving health checkups: a hospital-based study. Cholesterol. 2011;2011:314234.
112.Sampson Opoku, Yong Gan. Awareness, treatment, control, and determinants of dyslipidemia among adults in China. Sci Rep. 2021;11(1):10056.
113.Kim SJ, Kwon OD. Impact of a family history of cardiovascular disease on prevalence, awareness, treatment, control of dyslipidemia, and healthy behaviors: Findings from the Korea National Health and Nutrition Examination Survey. PLoS One. 2021;16(7):e0254907.
114.Boo S., Yoon Y.J. Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database: A cross-sectional analysis. Medicine. 2018;97:e13713.
115.Cheetham TC, Niu F. Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm 2013; 19: 367-373.
116.Krähenbühl S, Pavik-Mezzour I. Unmet needs in LDL-C lowering: When statins won’t do! Drugs 2016; 76: 1175-1190.
117.Fulcher J, O’Connell R, Voysey M, et al.. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397–405. 10.1016/S0140-6736(14)61368-4
118.Stone NJ, Robinson JG, Lichtenstein AH, et al.. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2013;2014:S1–45.
119.IMS Institute for Healthcare Informatics. Top 20 global therapy areas 2014. England and Wales: IMS Health MIDAS, 2014.
120.Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA2013;310:2451–2. 10.1001/jama.2013.281348
121.Hsing-Chun Hsieh ,Jason C Hsu , Christine Y Lu. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open 2017 May 17;7(5):e014150.
122.Svensson E, Nielsen RB, Hasvold P, et al.. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a danish population-based study. Clin Epidemiol 2015;7:213–23. 10.2147/CLEP.S78145
123.O’Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the health improvement network primary care data. Clin Epidemiol2016;8:123–32. 10.2147/CLEP.S104258
124Deambrosis P, Saramin C, Terrazzani G, et al.. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007;63:197–203. 10.1007/s00228-006-0239-3
125.Ferrajolo C, Arcoraci V, Sullo MG, et al.. Pattern of statin use in southern italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One 2014;9:e102146 10.1371/journal.pone.0102146
126.Svensson E, Nielsen RB, Hasvold P, et al.. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a danish population-based study. Clin Epidemiol 2015;7:213–23. 10.2147/CLEP.S78145
127.Salami JA, Warraich H, Valero-Elizondo J, et al.. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol 2017;2:56–65. 10.1001/jamacardio.2016.4700
128.Shih YT, Hung YT. The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health 2003;22:419–30.
129.Hwang LC, Bai CH. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 2006 Aug;105(8):626-35.
130.World Health Organization. Physical status: the use and interpretation of anthropometry. Geneva: WHO; 1995. Available online: https://www.who.int/publications/i/item/9241208546 (accessed on 20 Dec 2019)
131.Lin CC, Liu CS, Lai MM, Li CI, Chen CC, Chang PC et al. Metabolic syndrome in a Taiwanese metropolitan adult population. BMC Public Health. 2007; 7: 239
132.Huang, K.C. Obesity and its related diseases in Taiwan. Obes. Rev. 2008, 9 (Suppl. 1), 32–34
133.Kagan, A.; McGee, D.L. Serum cholesterol and mortality in a Japanese-American population: The Honolulu Heart program. Am. J. Epidemiol. 1981, 114, 11–20.
134.Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years: Experience of an international collaborative group. JAMA 1982, 248, 2853–2859.
135.Morris, D.L.; Borhani, N.O. Serum cholesterol and cancer in the hypertension detection and follow-up program. Cancer 1983, 52, 1754–1759.
136.Radisauskas, R.; Kuzmickiene, I. Hypertension, serum lipids and cancer risk: A review of epidemiological evidence. Med. (Kaunas) 2016, 52, 89–98.
137.Murai, T. Cholesterol lowering: Role in cancer prevention and treatment. Biol. Chem. 2015, 396, 1–11.
138.Tornberg, S.A.; Holm, L.E. Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N. Engl. J. Med. 1986, 315, 1629–1633.
139.Agnoli, C.; Grioni, S. Colorectal cancer risk and dyslipidemia: A case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol. 2014, 38, 144–151.
140.Houghton, J.; Lardieri, G.G. Effect of cholesterol levels on villous histology in colonic adenomas. Dig. Dis. Sci. 2000, 45, 896–899.
141.Lee, J.W.; You, N.Y. Statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS). Nutr. Metab. Cardiovasc. Dis. 2019, 29, 701–709.
142.Liu, Y.Q.; Tang, W.Z. Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies. Cancer Causes Control 2014, 25, 237–249.
143.Ye, P.; Xi, Y. Linking obesity with colorectal cancer: Epidemiology and mechanistic insights. Cancers 2020, 12, 1408.
144.Sekharam, M.; Nasir, A. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colorectal cancer in vitro. Anticancer Res. 2003, 23, 1517–1524.
145.Rouillier, P.; Senesse, P. Dietary patterns and the adenomacarcinoma sequence of colorectal cancer. Eur. J. Nutr. 2005, 44, 311–318.
146.Zhang, L.; Theodoropoulos, P.C. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Sci. Transl. Med. 2016, 8, 361ra140.
147.Liang, X.; Fan, X. Peroxisome proliferators-activated receptor gamma polymorphisms and colorectal cancer risk. J. Cancer Res. Ther. 2018, 14, S306–S310.
148.Niho, N.; Takahashi, M. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003, 63, 6090–6095.
149.Ashbeck, E.L.; Jacobs, E.T. Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1134–1143.
150.Saydah, S.H.; Platz, E.A. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 2003, 12, 412–418.
151.Borena, W.; Stocks, T. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011, 22, 291–299.
152.Stocks, T.; Lukanova, A. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011, 117, 2398–2407.
153.Ulmer, H.; Borena, W. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br. J. Cancer 2009, 101, 1202–1206.
154.McKeown-Eyssen, G. Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol. Biomark. Prev. 1994, 3, 687–695.
155.Kundu, J.K.; Surh, Y.J. Inflammation: Gearing the journey to cancer. Mutat. Res. 2008, 659, 15–30.
156.Esteve, E.; Ricart, W. Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin. Nutr. 2005, 24, 16–31.
157.Vekic, J.; Zeljkovic, A. Obesity and dyslipidemia. Metabolism 2019, 92, 71–81.
158.Pagliassotti, M.J.; Kim, P.Y. Endoplasmic reticulum stress in obesity and obesity-related disorders: An expanded view. Metabolism 2016, 65, 1238–1246.
159.Klop, B.; Elte, J.W. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients 2013, 5, 1218–1240.
160.Beloribi-Djefaflia, S.; Vasseur, S. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016, 5, e189.
161.Rolando, V.; Luca, D.L. Hints on ATGL implications in cancer: Beyond bioenergetic clues. Cell Death Dis. 2018, 9, 316.
162.Zimmermann, R.; Strauss, J.G. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004, 306, 1383–1386.
163.Yin, H.; Li, W. Adipose triglyceride lipase promotes the proliferation of. colorectal cancer cells via enhancing the lipolytic pathway. J. Cell. Mol. Med. 2021, 25, 3963–3975.
164.Hirano, T. Pathophysiology of Diabetic Dyslipidemia. J. Atheroscler. Thromb. 2018, 25, 771–782.
165.O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the health improvement network primary care data.Clin Epidemiol. 2016;8:123–32.
166.Hsieh HC, Hsu JC, Lu CY. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open. 2017;7(5):e014150.
167.Laleman N, Henrard S, van den Akker M, Goderis G, Buntinx F, Van Pottelbergh G, Vaes B. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord. 2018;18(1):209.
168.Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. J Am Med Assoc. 2015;314(17):
|